ATE121139T1 - Verfahren zur bestimmung der konzentration von antikoagulantien. - Google Patents

Verfahren zur bestimmung der konzentration von antikoagulantien.

Info

Publication number
ATE121139T1
ATE121139T1 AT92900357T AT92900357T ATE121139T1 AT E121139 T1 ATE121139 T1 AT E121139T1 AT 92900357 T AT92900357 T AT 92900357T AT 92900357 T AT92900357 T AT 92900357T AT E121139 T1 ATE121139 T1 AT E121139T1
Authority
AT
Austria
Prior art keywords
anticoagulatory
concentration
thrombin
inhibition
anticoagulants
Prior art date
Application number
AT92900357T
Other languages
English (en)
Inventor
Hendrik Coenraad Hemker
Robert Johan Wagenvoord
Hans-Juergen Kolde
Original Assignee
Baxter Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Diagnostics Inc filed Critical Baxter Diagnostics Inc
Application granted granted Critical
Publication of ATE121139T1 publication Critical patent/ATE121139T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974Thrombin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AT92900357T 1990-11-05 1991-10-30 Verfahren zur bestimmung der konzentration von antikoagulantien. ATE121139T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60934090A 1990-11-05 1990-11-05

Publications (1)

Publication Number Publication Date
ATE121139T1 true ATE121139T1 (de) 1995-04-15

Family

ID=24440379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900357T ATE121139T1 (de) 1990-11-05 1991-10-30 Verfahren zur bestimmung der konzentration von antikoagulantien.

Country Status (10)

Country Link
US (1) US5702912A (de)
EP (1) EP0509086B1 (de)
JP (1) JP3094165B2 (de)
AT (1) ATE121139T1 (de)
AU (1) AU650941B2 (de)
CA (1) CA2070813C (de)
DE (1) DE69108896T2 (de)
DK (1) DK0509086T3 (de)
ES (1) ES2073908T3 (de)
WO (1) WO1992007954A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4203980A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Verfahren zur bestimmung von hirudin und synthetischen thrombininhibitoren
AT397391B (de) * 1992-05-15 1994-03-25 Immuno Ag Verwendung von prothrombinfragmenten
US5308755A (en) * 1992-06-08 1994-05-03 Research Corporation Technologies, Inc. Method for measuring heparin
CA2150552C (en) * 1993-09-30 1999-12-21 Akikazu Takada Antithrombotic
CA2215162A1 (en) * 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US5985582A (en) * 1997-12-09 1999-11-16 Sigma-Aldrich Co. Thrombin-based assay for antithrombin III
WO1999038997A1 (fr) * 1998-01-30 1999-08-05 Yoshitomi Pharmaceutical Industries, Ltd. Procede de mesure de l'activite du cofacteur ii de l'heparine et boite de reactifs y relative
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
DE19904674A1 (de) * 1999-02-04 2000-08-31 Haemosys Gmbh Verfahren zur Bestimmung der Konzentration von Thrombininhibitoren
AUPP971299A0 (en) 1999-04-12 1999-05-06 South Eastern Sydney Area Health Service Procoagulant assay
EP1045250A1 (de) * 1999-04-12 2000-10-18 INSTRUMENTATION LABORATORY S.p.A. Test zur Auswertung der Funktionalität des Thrombin/Antithrombin Systemes
NZ521534A (en) * 2000-02-23 2004-10-29 Besst Test Aps Method for correlating blood coagulation activity with markers in urine
US6680177B2 (en) * 2001-12-07 2004-01-20 Cardiovascular Diagnostics, Inc. Low molecular weight heparin assay, system and reagent therefor
DE10330900B4 (de) * 2003-07-01 2006-09-14 Leibniz-Institut Für Polymerforschung Dresden E.V. Biomaterial mit einem modularen Beschichtungssystem zur Anwendung in Medizinprodukten mit direktem Blutkontakt
CA2566411A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor xa and/or anti factor iia activities
WO2005116623A2 (en) 2004-05-17 2005-12-08 Medtronic, Inc. Point of care heparin determination system
PT1748781E (pt) * 2004-05-27 2013-01-22 Baxter Int Processos para o tratamento de distúrbios de hemorragias utilizando polissacarídeos sulfatados
DE102005038418A1 (de) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Faktor Xa-basierter Heparinassay unter Verwendung einer Heparin-modifizierenden Komponente
DE102006035580A1 (de) * 2006-07-27 2008-02-14 Csl Behring Gmbh Bestimmung der biologischen Aktivität von Heparin in AT III-haltigen Präparationen
EP1918718A1 (de) 2006-10-31 2008-05-07 Roche Diagnostics GmbH Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
WO2009023538A1 (en) * 2007-08-10 2009-02-19 Mayo Foundation For Medical Education And Research Methods and devices for detecting thrombin generation
EP2471945A1 (de) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Bestimmung von Inhibitoren der Gerinnung
JP6087775B2 (ja) * 2013-09-13 2017-03-01 薫 梅野 ハンドバイブレーターおよびハンドバイブレーター用連結具
WO2018128002A1 (ja) * 2017-01-06 2018-07-12 ソニー株式会社 血液凝固系解析装置、血液凝固系解析システム、血液凝固系解析方法、及び血液凝固系解析用プログラム、並びに、出血量予測装置、出血量予測システム、出血量予測方法、及び出血量予測用プログラム
CN110514851A (zh) * 2019-08-28 2019-11-29 深圳麦科田生物医疗技术有限公司 血小板抑制率的检测方法和检测试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2812943C3 (de) * 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
DE3005540A1 (de) * 1980-02-14 1981-08-20 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und reagens zur bestimmung der biologischen aktivitaet von heparin im plasma
EP0049877B1 (de) * 1980-10-09 1984-05-23 Roche Diagnostics GmbH Verfahren und Reagenz zur Bestimmung von Antithrombin-BM
US4473639A (en) * 1982-09-15 1984-09-25 Miles Laboratories, Inc. Reagent strip test for antithrombin-III
US4851336A (en) * 1985-09-05 1989-07-25 Yin E Thye Composition, kit, and method for assaying heparinano a method for making the composition
DE3536903A1 (de) * 1985-10-16 1987-04-16 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung von protein c
IT1230744B (it) * 1989-07-07 1991-10-29 Instrumentation Lab Spa Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano.
NL8902406A (nl) * 1989-09-27 1991-04-16 Hendrik Coenraad Hemker Prof D Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.

Also Published As

Publication number Publication date
JPH05503223A (ja) 1993-06-03
AU1015492A (en) 1992-06-25
CA2070813C (en) 1996-10-29
ES2073908T3 (es) 1995-08-16
WO1992007954A1 (en) 1992-05-14
AU650941B2 (en) 1994-07-07
CA2070813A1 (en) 1992-05-06
US5702912A (en) 1997-12-30
JP3094165B2 (ja) 2000-10-03
DE69108896D1 (de) 1995-05-18
DK0509086T3 (da) 1995-07-03
EP0509086B1 (de) 1995-04-12
EP0509086A1 (de) 1992-10-21
DE69108896T2 (de) 1995-08-24

Similar Documents

Publication Publication Date Title
ATE121139T1 (de) Verfahren zur bestimmung der konzentration von antikoagulantien.
Teien et al. Heparin assay in plasma: A comparison of five clotting methods
EP0632270A4 (de) Verfahren zur bestimmung der aktivität des blutgerinnungsfaktors xiii und reagentiensatz dafür.
US20090087870A1 (en) Hematological assay and kit
ATE315233T1 (de) Verfahren zur bestimmung des antikoagulatorischen potentials einer probe und verfahren zur bestimmung der glykosilierung von thrombomodulin
Kahle et al. Antithrombin III I. Evaluation of an automated antithrombin III method
AU694931B2 (en) A method for detecting disturbances of the protein C/protein S system
ES2152531T3 (es) Prueba para determinar el riesgo de trombosis.
US4918001A (en) Method for the determination of protease inhibitors
DE69216583T2 (de) Bestimmungsverfahren fur protein s
ATE40718T1 (de) Verfahren zur bestimmung von fibrinmonomer in plasma.
ATE136367T1 (de) Verfahren zur bestimmung von hirudin und synthetischen trhombininhibitoren
US5320945A (en) Method and reagent for the determination of antithrombin III
ATE43641T1 (de) Bestimmung von prokallikrein.
EP0491895B1 (de) Chromogenes bestimmungsverfahren für den faktor viii:ca
ATE5200T1 (de) Verfahren und reagens zur bestimmung von betalactamasen.
US7923217B2 (en) Specificity in the determination of antithrombin
JP2024095611A (ja) フィブリノゲンを決定する方法
Cumming et al. The assay of factor VIII: C in heparinized plasma: a polybrene neutralization method

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee